🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to scientists.

An International Challenge

Gonorrhoea infections are escalating around the world, with data suggesting over 82 million instances per year. Notably increased rates are seen in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the face of rising global incidence, escalating drug resistance and the very limited therapeutic options at this time.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to develop it.

“This approval represents a huge turning point in the therapy of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Data and Worldwide Availability

According to data released by a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This places it at an equal footing with the current standard treatment, which involves a dual-drug approach. The research included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the rights to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have shared positive views. The availability of a single-dose, oral treatment like this is hailed as a "critical tool" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea globally.